Posted in ‘Prescription Cancer Drugs’ 10 October 2010 Side effects of the quadrivalent human papillomavirus vaccine (Gardasil) have been pretty much what researchers expected, the CDC and FDA reported, although there were enough instances of of fainting and blood clots reported to worry critics. With more than 23 million doses of the vaccine distributed, most […]
HPV: Who immunizes? Who pays?
By: Lynn Shapiro 08 October 2010 The anticipated approval of Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Merck] for women 27 to 45 years of age has thrown the issue of vaccine reimbursement for pharmacists into the spotlight. A Merck spokeswoman told Drug Topics that the company expects to hear […]
Flu, HPV, norovirus vaccines to be tested here
By: Patti Singer, Staff Writer 04 October 2010 If engineers strive to make a better mousetrap, scientists seek more effective vaccines. Over the next few months, three of their latest efforts will be tested in Rochester. The University of Rochester Medical Center is recruiting volunteers to test the first licensed vaccine against norovirus, commonly called […]
Cervarix licence extended
Published in HealthcareRepublic 01 October 2010 The marketing authorisation for Cervarix has been updated to show that it offers broader protection against human papillomavirus (HPV) than first thought. Read the entire article here.
Gardasil Anal Cancer Indication to Face FDA Advisory Committee Scrutiny
By: S. Sutter 27 September 2010 Merck’s bid to further expand the label for its human papillomavirus vaccine Gardasil – this time for the prevention of anal cancer and anal dysplasia – will face FDA advisory committee scrutiny in November. The Vaccines and Related Biological Products Advisory Committee will meet on Nov. 17 to discuss […]
- « Previous Page
- 1
- …
- 427
- 428
- 429
- 430
- 431
- …
- 448
- Next Page »
